iMCD-TAFRO cases
| Therapy . | Patients (n) . | Response (%) . | No response (%) . | Treatment failure (%) . |
|---|---|---|---|---|
| All therapies | 49 | 65/98 (66) | 33/98 (34) | 52/98 (53) |
| Corticosteroid monotherapy | 25 | 9/25 (36) | 16/25 (64) | 18/25 (72) |
| Cyclophosphamide-based cytotoxic chemotherapy | 14 | 13/14 (93) | 1/14 (7) | 4/14 (29) |
| Rituximab with cytotoxic agent | 1 | 1/1 (100) | 0/1 (0) | 0/1 (0) |
| Rituximab without cytotoxic agent | 10 | 9/10 (90) | 1/10 (10) | 4/10 (40) |
| Cytotoxic regimen (without cyclophosphamide or rituximab) | 3 | 2/3 (67) | 1/3 (33) | 1/3 (33) |
| Tocilizumab with or without steroids | 20 | 15/20 (75) | 5/20 (25) | 10/20 (50) |
| Siltuximab with or without steroids | 1 | 1/1 (100) | 0/1 (0) | 1/1 (100) |
| Cyclosporine A (without cytotoxic agent) | 8 | 6/8 (75) | 2/8 (25) | 2/8 (25) |
| Immunomodulators: other than cyclosporine A (without cytotoxic agent) | 9 | 5/9 (56) | 4/9 (44) | 5/9 (56) |
| Other | 7 | 4/7 (57) | 3/7 (43) | 7/7 (100) |
| Therapy . | Patients (n) . | Response (%) . | No response (%) . | Treatment failure (%) . |
|---|---|---|---|---|
| All therapies | 49 | 65/98 (66) | 33/98 (34) | 52/98 (53) |
| Corticosteroid monotherapy | 25 | 9/25 (36) | 16/25 (64) | 18/25 (72) |
| Cyclophosphamide-based cytotoxic chemotherapy | 14 | 13/14 (93) | 1/14 (7) | 4/14 (29) |
| Rituximab with cytotoxic agent | 1 | 1/1 (100) | 0/1 (0) | 0/1 (0) |
| Rituximab without cytotoxic agent | 10 | 9/10 (90) | 1/10 (10) | 4/10 (40) |
| Cytotoxic regimen (without cyclophosphamide or rituximab) | 3 | 2/3 (67) | 1/3 (33) | 1/3 (33) |
| Tocilizumab with or without steroids | 20 | 15/20 (75) | 5/20 (25) | 10/20 (50) |
| Siltuximab with or without steroids | 1 | 1/1 (100) | 0/1 (0) | 1/1 (100) |
| Cyclosporine A (without cytotoxic agent) | 8 | 6/8 (75) | 2/8 (25) | 2/8 (25) |
| Immunomodulators: other than cyclosporine A (without cytotoxic agent) | 9 | 5/9 (56) | 4/9 (44) | 5/9 (56) |
| Other | 7 | 4/7 (57) | 3/7 (43) | 7/7 (100) |
These were compiled from published case reports and small series.
n, number of subjects treated in each treatment regimen category, with a total of 98 regimens evaluated. Other includes plasma exchange (n = 3), plasma exchange + corticosteroids (n = 2), polymyxin B–immobilized fiber column direct hemoperfusion and cytokine absorption (n = 1), allogeneic stem cell transplant (n = 1). Please refer to supplemental appendix 1 for complete list of references.